The aim of the present study is to evaluate the value of hyaluronan (HA) as a biomarker of sepsis in patients not showing sepsisassociated liver dysfunction and to investigate the relationship between HA level and disease severity. Sepsis patients that had been followed-up between 2015 and 2016 in intensive care units (ICU) of Erciyes University Hospital were included in this prospective study. Sepsis was defined according to the 2013 Sepsis Survival Campaign Guidelines. The patients were classified as sepsis, severe sepsis, and septic shock. Blood samples were collected from the patients on the first and the third days to measure the HA level. The demographic characteristics, the duration of intensive care unit stay, and mortality data of the patient and the control groups were analyzed. A total of 46 patients and 30 control subjects were evaluated. HA levels were found to be higher in the sepsis group than the others. HA was neither a predictor of the disease mortality, nor was it correlated with the inflammatory markers, C-reactive protein (CRP), and procalcitonin (PCT). HA is not a sepsis biomarker in the patients with sepsis who do not show sepsis-associated liver dysfunction.
___
1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Garcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
2. Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 2012; 10: 701-706.
3. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43: 304- 307.
4. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth 2012; 108: 384-394.
5. Marik P, Bellomo R. A rational approach to fluid therapy in sepsis. Br J Anaesth 2016; 116: 339- 349.
6. Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol 2014; 10: 37-47.
7. Kolsen-Petersen JA. The endothelial glycocalyx: the great luminal barrier. Acta Anaesthesiol Scand 2015; 59: 137-139.
8. Schött U, Solomon C, Fries D, Bentzer P. The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review. Scand J Trauma Resusc Emerg Med 2016; 24: 48.
9. Zeng Y, Tarbell JM. The adaptive remodeling of endothelial glycocalyx in response to fluid shear stress. PLoS ONE 2014; 9: e86249.
10. Lennon FE, Singleton PA. Hyaluronan regulation of vascular integrity. Am J Cardiovasc Dis 2011; 1: 200-213.
11. Henry CB, Duling BR. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol 1999; 277: 508-514.
12. Fraser JR, Engström-Laurent A, Nyberg A, Laurent TC. Removal of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis. J Lab Clin Med 1986; 107: 79-85.
13. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26: 802-809.
14. Yagmur E, Koch A, Haumann M, Kramann R, Trautwein C, Tacke F. Hyaluronan serum concentrations are elevated in critically ill patients and associated with disease severity. Clin Biochem 2012; 45: 82-87.
15. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
16. Berg S. Hyaluronan turnover in relation to infection and sepsis. J Intern Med 1997; 242: 73- 77.
17. Berg S, Jansson I, Hesselvik FJ, Laurent TC, Lennquist S, Walther S. Hyaluronan: relationship to hemodynamics and survival in porcine injury and sepsis. Crit care Med 1992; 20: 1315-1321.
18. Berg S. Hyaluronan in sepsis. Acta Anaesthesiol Scand 1995; 39: 277.
19. Nelson A, Berkestedt I, Schmidtchen A, Ljunggren L, Bodelsson M. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock 2008; 30: 623-627.
20. Köhler M, Kaufmann I, Briegel J, et al. The endothelial glycocalyx degenerates with increasing sepsis severity. Crit Care 2011; 15: 22.
21. Gudowska M, Gruszewska E, Panasiuk A, et al. Hyaluronicacid concentration in liver diseases. Clin Exp Med 2016; 16: 523-528.
22. Jensen JU, Bouadma L. Why biomarkers failed in sepsis. Intensive Care Med 2016; 42: 2049-2051.